Skip Navigation LinksHome > September 2006 - Volume 43 - Issue 1 > Mortality in the Highly Active Antiretroviral Therapy Era: C...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000233310.90484.16
Clinical Science

Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study

Palella, Frank J. Jr MD*; Baker, Rose K. MA†; Moorman, Anne C. BSN, MPH‡; Chmiel, Joan S. PhD*; Wood, Kathleen C. BSN†; Brooks, John T. MD‡; Holmberg, Scott D. MD, MPH‡; HIV Outpatient Study Investigators

Free Access
Article Outline
Collapse Box

Author Information

From the *Feinberg School of Medicine, Northwestern University, Chicago, IL; †Cerner Corporation, Vienna, VA; and ‡Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA.

Received for publication January 20, 2006; accepted June 9, 2006.

This work was supported by Centers for Disease Control and Prevention.

The HIV Outpatient Study investigators are listed in Appendix A.

Reprints: Frank Palella, Jr., MD, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Suite 200, 676 North Saint Clair, Chicago, IL 60611 (e-mail:

Collapse Box


Background: AIDS-related death and disease rates have declined in the highly active antiretroviral therapy (HAART) era and remain low; however, current causes of death in HAART-treated patients remain ill defined.

Objective: To describe mortality trends and causes of death among HIV-infected patients in the HAART era.

Design: Prospective, multicenter, observational cohort study of participants in the HIV Outpatient Study who were treated from January 1996 through December 2004.

Measurements: Rates of death, opportunistic disease, and other non-AIDS-defining illnesses (NADIs) determined to be primary or secondary causes of death.

Results: Among 6945 HIV-infected patients followed for a median of 39.2 months, death rates fell from 7.0 deaths/100 person-years of observation in 1996 to 1.3 deaths/100 person-years in 2004 (P = 0.008 for trend). Deaths that included AIDS-related causes decreased from 3.79/100 person-years in 1996 to 0.32/100 person-years in 2004 (P = 0.008). Proportional increases in deaths involving liver disease, bacteremia/sepsis, gastrointestinal disease, non-AIDS malignancies, and renal disease also occurred (P = <0.001, 0.017, 0.006, <0.001, and 0.037, respectively.) Hepatic disease was the only reported cause of death for which absolute rates increased over time, albeit not significantly, from 0.09/100 person-years in 1996 to 0.16/100 person-years in 2004 (P = 0.10). The percentage of deaths due exclusively to NADI rose from 13.1% in 1996 to 42.5% in 2004 (P < 0.001 for trend), the most frequent of which were cardiovascular, hepatic, and pulmonary disease, and non-AIDS malignancies in 2004. Mean CD4 cell counts closest to death (n = 486 deaths) increased from 59 cells/μL in 1996 to 287 cells/μL in 2004 (P < 0.001 for trend). Patients dying of NADI causes were more HAART experienced and initiated HAART at higher CD4 cell counts than those who died with AIDS (34.5% vs 16.8%, respectively, received HAART for 4 of more years, P < 0.0001; 22.4% vs 7.8%, respectively, initiated HAART with CD4 cell counts of more than 350 cells/μL, P < 0.001).

Conclusions: Although overall death rates remained low through 2004, the proportion of deaths attributable to non-AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies. Longer time spent receiving HAART and higher CD4 cell counts at HAART initiation were associated with death from non-AIDS causes. CD4 cell count at time of death increased over time.

Marked and sustained reductions in AIDS-related death and opportunistic disease have been observed as a consequence of the extensive use of highly active antiretroviral therapy (HAART) since 1996 in the United States and Europe.1-7 These benefits have been observed across diverse patient populations and have resulted in prolonged disease-free survival, durable HIV virologic suppression, immunologic (CD4 cell) repletion, and reductions in hospitalization rates.8 During this time, new morbidities have been observed among HAART-treated persons that have been variably ascribed to specific antiretroviral therapy (ART) received9,10 and to factors other than treatment such as stage of underlying HIV disease, baseline host (patient age, race, and sex), and other factors.11,12 Although AIDS-related death and opportunistic disease rates have remained low, increased attention has been paid to the treatment and consequences of important comorbidities such as lipoatrophy, lipoaccumulation, insulin resistance with consequent hyperglycemia, hyperlipidemia, cardiovascular disease, osteopenia, and, less commonly, symptomatic hyperlactatemia.11-18 Another consequence of improved long-term management of HIV infection has been recognition of the increased importance of providing effective treatment of chronic coinfections such as hepatitis B and C.19-21

Detailed descriptions of the spectrum of illnesses encountered among HAART-treated persons whose HIV infection is under control and of the conditions that are likely to result in death in such persons are lacking, although there are some reports profiling causes of death among person-with-AIDS diagnoses early in the HAART era,22 among non-US populations that were less extensively HAART-treated,23,24 and among women only.25 We sought to evaluate the most recent trends in mortality and morbidity among mostly HAART-treated persons in the HIV Outpatient Study (HOPS), a large geographically and ethnically diverse cohort of HIV-infected persons in the United States. We present data profiling rates and causes of death and disease (both opportunistic and nonopportunistic) over time among HOPS participants treated since 1996.

Back to Top | Article Outline


The HIV Outpatient Study

The HOPS is an ongoing prospective observational cohort study into which patients have been continuously recruited and followed since 1993.26 Study sites are 12 clinics (7 university, 3 public, and 2 private) in 10 US cities that provide care for about 3000 HIV-infected patients per year. More than 8000 HOPS patients have been seen in more than 30,000 person-years of observation since 1993. All HOPS clinicians have extensive experience treating HIV-infected patients. Information is abstracted from outpatient charts at each visit and entered electronically by trained staff, compiled centrally, then reviewed and edited before being analyzed. Information abstracted includes demographic characteristics and risk factors for HIV infection, symptoms, diagnosed diseases (both definitive and presumptive), medications prescribed, including dose and duration, and laboratory values, including CD4 cell counts and measurements of plasma HIV-1 RNA (viral load).

Since 2000, HOPS sites have used a standardized mortality data entry template designed to capture patient information near the time of death, including primary, secondary, and contributing causes of death, hospitalization chart information, and antiretroviral drug use. This mortality data template was used to collect information for deaths that occurred from January 1, 1996, to the end of the observation period (December 31, 2004) analyzed. As sites identified and recorded known deaths among their HIV-infected patient population, trained data abstractors completed the mortality form using data available from sources, including one or more of the following: death certificates, medical charts, discharge summaries, autopsy reports, and direct discussion with clinicians who had cared for the deceased. Whenever possible, any additional information available from clinicians (physicians and nurses) involved with the care of the deceased was used.

Back to Top | Article Outline
Selection of Patients for Analysis

We analyzed data from 6945 participants in the HOPS who were seen at least twice from January 1, 1996, to December 31, 2004, using HOPS data updated as of December 31, 2005. Data were censored at the end of 2004 to allow adequate time for data entry lag that occurs in the identification and documentation of deaths. End of follow-up was defined as the date of first occurrence of the following: (1) last patient contact (physician/clinic visit, hospitalization, home nursing visit, or telephone contact) plus 180 days, (2)date of death, or (3) December 31, 2004. Only deaths that occurred during follow-up were included in this analysis.

Back to Top | Article Outline

We calculated the annual number of deaths per 100 person-years between 1996 and 2004. Up to 5 primary and secondary causes of death could be entered for each patient, and all documented death causes were analyzed. Causes of death that were non-AIDS-defining illnesses (NADIs) were classified by the first author into the following disease categories for analysis: bacteremia/sepsis, central nervous system disorders, pulmonary diseases, hepatic diseases, renal diseases, cardiovascular diseases, gastrointestinal diseases, and nonopportunistic malignancies. We calculated annual death rates that involved at least one of these disease categories and annual death rates involving AIDS.

We also evaluated HAART use over time in relation to death rates. The HAART definition used for this analysis included antiretroviral regimens that fell into one of the following categories: (a) 3 antiretrovirals, one of which was either a protease inhibitor (PI) or a nonnucleoside reverse-transciptase inhibitor; (b) 3 nucleoside reverse-transciptase inhibitors, one of which was abacavir or tenofovir (TDF) (except for the regimens abacavir + TDF + lamivudine (3TC) and didanosine + TDF + 3TC; (c) 2 full-dose PIs; and (d) a boosted PI with an nonnucleoside reverse-transciptase inhibitor.

We evaluated CD4 cell counts within 6 months of death by year of death, by duration of time spent receiving HAART, and by CD4 cell count at HAART initiation, all stratified by cause of death. If a patient's ART discontinuation date was not known at the time of death, this date was imputed to be 90 days after the last visit with a HOPS clinician.

All analyses were done using a standard statistical package (SAS version 8.2, SAS Institute, Cary, NC). Tests for trend in death rates were done using log-linear modeling of death rates over time assuming a Poisson distribution where rates were calculated based upon numbers of deaths divided by 100 person-years.27 Tests for trend by age over time were done using general linear modeling. Reported P values are not adjusted for multiple comparisons.

Back to Top | Article Outline


The 6945 patients analyzed had a median follow-up of 39.2 months. From 1996 through 2004, we identified 702 deaths. Death rates declined from 7.0 deaths per 100 person-years in 1996 to 1.3 deaths per 100 person-years in 2004 (P = 0.008 for trend; Fig. 1) and stabilized at approximately 2.0 deaths per 100 person-years between 1999 and 2002, after which little further decline was noted. Over this same period, HAART utilization rates rose from 43% of patients in 1996 to 82% in 2004. Since 1999, about 78% of HOPS participants received HAART.

Figure 1
Figure 1
Image Tools

Characterization of those who died by age, sex, race, HIV risk, and insurance status (Table 1) revealed that death rates dropped for all groups of patients. However, death rates were higher among African Americans, those who were publicly insured, and those with a history of injection drug use. Median age at death increased from 39 years in 1996 to 49 years in 2004 (P < 0.001), as did the median age of HOPS participants overall (from 38 to 44 years), although not as steeply.

Table 1
Table 1
Image Tools

We were able to obtain at least one primary and/or secondary cause of death for 554 (79%) of the 702 deaths. We compared patients for whom causes of death were known versus not known. We found no significant differences with respect to sex, age, HIV risk behavior, months of HAART use, CD4 cell counts, or plasma HIV viral loads within 6 months ofdeath. Persons for whom no cause of death information wasavailable were more likely to be African American (P = 0.011), have public insurance (P = 0.011), and have had shorter lengths of follow-up (P = 0.0009) than those for whom cause of death information was known.

Deaths for which AIDS-related causes were included among reported death causes decreased from 3.79 per 100 person-years in 1996 to 0.32 per 100 person-years in 2004 (Table 2A). Deaths for which no primary or secondary causes were available also significantly decreased over time from 2.28 per 100 person-years to 0.42 per 100 person-years (P < 0.0001). We observed significant reductions over time in deaths for which neurologic, cardiovascular, and pulmonary disorders were cited as death causes with or without a concurrent opportunistic infection (Table 2A). Hepatic disease was the only reported cause of death that increased in rate over time (albeit not significantly), from 0.09 per 100 person-years in 1996 to 0.16 per 100 person-years in 2004 (P = 0.100), peaking in 2002 (0.53 per 100 person-years). Among patients dying of hepatic disease, the proportion who were coinfected with hepatitis B or C increased from 50% in 1996 to 80% in 2004 (P = 0.079 for trend). If deaths that included an AIDS-related cause were excluded, a significant decrease in NADI-associated deaths was observed for deaths associated with pulmonary disease from 0.37 per 100 person-years in 1996 to 0.13 per 100 person-years in 2004 (P = 0.038).

Table 2
Table 2
Image Tools

Evaluation of cause-specific deaths as a proportion of all deaths in a given year (Table 2B) revealed decreases over time in the proportion of deaths due to AIDS (P = 0.008) and unknown causes (P = 0.021), with concomitant increases in the proportion of deaths associated exclusively with NADIs from 13.1% in 1996 to 42.5% in 2004 (P < 0.001). More specifically, proportional increases in deaths caused by bacteremia/sepsis, gastrointestinal disease, hepatic disease, non-AIDS malignancies, and renal disease were observed. When specific NADI death causes were evaluated as a proportion of deaths for which only NADI causes were documented, we noted no significant trends except for a decrease in pulmonary illness-related deaths, decreasing from 40% in 1996 to 23.5% in 2004 (P = 0.039 for trend). The most frequently reported NADI causes in 2004 (regardless of trend) were cardiovascular, hepatic and pulmonary disease, and non-AIDS malignancies.

CD4 cell counts nearest to time of death were known for 486 (69%) of deaths. Mean CD4 cell count values increased over time from 59 cells/μL in 1996 to 287 cells/μL in 2004 (P < 0.001 for trend) for all observed deaths. This increase was greater for deaths due exclusively to NADI causes (Fig. 2) for which mean CD4 cell counts closest to death rose from 76 cells/μL in 1996 to 354 cells/μL in 2004 (P < 0.0001 for trend). In comparison, among AIDS-related deaths, CD4 cell counts closest to death increased from 42 cells/μL in 1996 to 130 cells/μL in 2004 (P = 0.014 for trend).

Figure 2
Figure 2
Image Tools

Complete ART history was known for 569 (81%) of the 702 deaths. CD4 cell counts at time of HAART initiation and overall HAART use duration were significantly associated with cause of death category (AIDS- vs NADI-associated cause of death; Table 3). Among exclusively NADI-associated deaths, 34.7% had received HAART for 4 or more years compared with 16.8% of patients dying with AIDS-related diseases (overall P < 0.0001). CD4 cell count measurements documented within 6 months before HAART initiation were available for 334 of the deceased. Evaluation of these revealed that 22.4% of patients dying of NADI causes versus 7.8% of patients dying of AIDS-related illness initiated HAART with CD4 more than 350 cells/μL (P = 0.001). Patients who died exclusively from NADI causes were also more likely to have been receiving ART at the time of death (51.8%) compared with 40.4% of patients with AIDS death causes (P = 0.015). However, knowledge of ART receipt status at the time of death was known for more persons with exclusively NADI causes of death than those with AIDS-related death causes.

Table 3
Table 3
Image Tools
Back to Top | Article Outline


Our review of causes of death among a large and demographically diverse population of HIV-infected persons in the post-HAART era revealed several major findings. First, while overall death rates remained quite low through the ninth year of highly prevalent HAART use in the HOPS, the annual percentage of deaths with at least one non-AIDS cause of death increased progressively over time, accounting for well over half of all deaths by the end of 2004. During the period 2000 to 2004, non-AIDS death causes prominently included hepatic, pulmonary, and cardiovascular illnesses. Compared with persons dying from AIDS-related conditions, persons with exclusively non-AIDS death causes initiated ART at higher CD4 cell counts, were more HAART experienced, and were more likely to have received HAART near the time of death. Consonant with these findings, mean CD4 cell counts proximal to the time of death and age at death increased significantly over time. Long-term HIV suppression, CD4 cell count stability or improvement, and clinical benefits provided by ART increasingly allowed HOPS participants to avoid AIDS-defining illnesses and delay death even if they had a history of a prior AIDS-defining illness. As a result, more prolonged survival allowed chronic underlying comorbid conditions or risks for such conditions to become more clinically relevant, particularly liver disease (especially chronic coinfection with viral hepatitis), hypertension, diabetes, cardiovascular illness, pulmonary disease, and non-AIDS malignancies.

HIV treatments themselves may have resulted in conditions that contributed to an increased likelihood of certain deaths. Our data can be interpreted to imply that the increased proportion of non-AIDS-related causes of death (from multiple illness categories) can be attributed to longer ART treatment (eg, PI use and myocardial infarctions as seen in this cohort),13 but those with longer ART treatment histories also were living longer with comorbid illnesses and chronic risks for illnesses other than AIDS. Likewise, recent reports from this cohort and others demonstrate mortality benefits of initiating ART earlier in the course of HIV infection (ie, at higher CD4 cell counts)28 and the survival benefits of maintaining continuous HAART even when higher CD4 cell counts have been achieved.29 Thus, while appreciating the shift in spectrum of illnesses contributing to death among those living longer in the HAART era, it is important to emphasize that any contributions of ART to the risk for NADIs are clearly outweighed by the benefits consequent to HAART's use in reducing overall mortality and AIDS-related morbidity. These benefits are dramatic, durable, and unequivocal.1-7

It is also possible that HAART-associated immune reconstitution may have increased the risk for NADIs via chronic immune activation and upregulation of proinflammatory cytokines. This has been suggested in recent analyses from this cohort and others profiling increased rates of specific non-AIDS-related morbidities.30-32

Given that our findings show increasing mean CD4 values at death among HIV-infected HAART-treated persons, are CD4 cell counts losing their predictive value in the assessment of death risk in this population? Although this seems to be true for both those dying with or those dying without AIDS-defining illnesses, it needs to be interpreted in light of our central findings-that AIDS-associated death rates remained durably low among HAART-treated persons, and such deaths are increasingly likely to occur as a consequence of NADIs, particularly among persons with higher CD4 cell counts and those who were receiving HAART near the time of death. There was no evidence that AIDS-associated opportunistic diseases occurred and contributed to death despite increasing CD4 counts (particularly among those with CD4 counts approximately >150 cells/μL) nearest to time of death, nor that there was an overt dissociation between CD4 counts and opportunistic infection risk. However, we did not undertake a formal predictor analysis to assess the ability of CD4 cell counts measured near the time of death to predict death risk. This has been done in other studies.33

There are unavoidable limitations in an analysis of an observational cohort of HIV-infected ambulatory outpatients. First, we lack a readily available age- and risk-matched HIV-seronegative population to whom we can easily compare our death rates from non-AIDS-related illnesses. As successfully treated HIV patients survive longer with higher CD4 cell counts, it is reasonable to anticipate that their diseases will more closely resemble those of comparable non-HIV-infected persons. Second, the HOPS is a dynamic cohort in which all patients are not necessarily followed continuously throughout the course of their HIV infection (ie, patients may enter or leave the cohort any time during the observation period). However, we believe that a major strength of this analysis is that it profiles mortality rates and causes among a heterogeneous and representative group of HIV-infected persons who received care from their own HIV clinicians. Third, discernment of precise causes of death is always a challenge. We gathered cause of death information from meticulous review of medical records with input from clinicians caring for patients near the time of death. Moreover, the proportion of deaths for which there was no death cause information available decreased over time. Because many of the deceased died while hospitalized, and we were able to undertake systematic and careful review of inpatient as well as outpatient records, we may have better classification of death causes than other published reports. Short of the routine performance of autopsies, we believe we thoroughly accessed available clinical data from existing sources. Finally, some recent reports have discussed the role of more optimal medication adherence upon improved survival among HAART-treated persons with advanced HIV infection.34 Although we did not have precise measurements of medication adherence for all of the deceased profiled in this report, a recent report from the HOPS suggests a very high rate of HAART medication adherence in our cohort.35

In conclusion, in an era during which HIV-infected persons routinely live longer as a result of timely intervention with HAART, it is important for clinicians to be aware that other underlying, nontraditionally HIV-related conditions are ever more likely to figure prominently in the risk for death and disease. These conditions should be aggressively screened for, monitored, and treated. Chronic liver disease (especially in chronic viral hepatitis-coinfected persons), cardiovascular and pulmonary disease, and non-AIDS malignancies loom particularly large among these nontraditionally HIV-related morbidities that usually require specific ongoing targeted therapy. Although HIV-infected persons are clearly living longer as a consequence of effective HAART, they may be dying earlier than those in the general population, albeit not from traditionally HIV-associated conditions. These observations underscore the need for improved vigilance on the part of clinicians in maintaining proactive and preventive medical care and routine screening for all HIV-infected persons receiving HAART.

Back to Top | Article Outline


1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality in an ambulatory HIV-infected population. N Engl J Med. 1998;338:853-860.

2. Detels R, Tarwater P, Phair J, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infection before and after AIDS diagnosis. AIDS. 2001;15:347-355.

3. Palella FJ Jr, Moorman AC, Chmiel J, et al. Durability and predicators of success of highly active antiretroviral therapy (HAART) for ambulatory HIV-infected patients. AIDS. 2002;16:1-10.

4. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.

5. Vittinghoff E, Scheer S, O'Malley PM, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999;179:717-720.

6. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352(9142):1725-1730.

7. Mocroft A, Ledergerber B, Katlama C, et al. Related articles, links decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22-29.

8. Fleishman JA, Hellinger FH. Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study. J Acquir Immune Defic Syndr. 2003;34:102-110.

9. Dubé MP, Johnson DL, Currier JS, et al. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713-714. [letter].

10. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.

11. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.

12. Lichtenstein KA, Delaney KM, Armon C, et al. Development of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56.

13. Holmberg SD, Moorman AC, Williamson JC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748.

14. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490.

15. Loiseau-Pérès S, Delaunay C, Poupon S, et al. Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine. 2002;69:482-485.

16. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(suppl):S85-S90.

17. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002;31:257-275.

18. Tripuraneni NS, Smith PR, Weedon J, et al. Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature. AIDS Patient Care STDS. 2004;18:379-384.

19. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis is related to CD4 depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis. 2001;183:134-137.

20. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.

21. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.

22. Louie JK, Ling CH, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. JID. 2002;186:1023-1027.

23. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy; emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34(1):121-130.

24. Mocroft A, Gatell J, Reiss P, et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS. 2004;18(17):2333-2337.

25. Smith D, Gardner L, Phelps R, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health. 2005;80:676-688.

26. Moorman AC, Holmberg SD, Marlowe SI, et al. Changing conditions and therapies of ambulatory HIV-infected patients: the HIV Outpatient Study (HOPS). Ann Epidemiol. 1999;9:349-357.

27. Kleinbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariable Methods, 2nd ed. Boston, MA: PWS-Kent Publishing Company; 1988.

28. Palella FJ Jr, Knoll MD, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626.

29. El-Sadr W, Neaton J, for the SMART Study Investigators. Episodic CD-guided use of ART is inferior to continuous therapy: results of the SMART Study. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Paper 106LB.

30. Patel P, Novak R, Tong T, et al. Incidence of non-AIDS-defining malignancies in the HIV Outpatient Study. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA. Abstract 81.

31. Lichtenstein K, Armon C, Buchacz K, Moorman A, Wood K, et al. Early, uninterrupted ART is associated with improved outcomes and fewer toxicities in the HIV Outpatient Study (HOPS). 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Paper 769.

32. Williams P, Wu J, Cohn S, Koletar S, McCutchan J, Murphy R, Currier J, and the ACTG 362 Team. Risk of cardiovascular disease in HIV-infected adults with immune reconstitution. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Paper 867.

33. Weber R, Friis-Moller N, Sabin C, Reiss P, D'Arminio Monforte A, et al. HIV and non-HIV related deaths and their Relationship to immunodeficiency: The D:A:D Study. 12th Conference on Retroviruses and Opportunistic Infections (CROI); February 22-25, 2005; Boston, MA. Paper 595.

34. Wood E, Hogg R, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 109 cells/L. Ann Intern Med. 2003;139:810-816.

35. Deloria-Knoll M, Chmiel JS, Moorman AC, et al. Factors related to and consequences of adherence to antiretroviral therapy in ambulatory HIV-infected patients. AIDS Clin Care. 2004;18(12):721-727.

Back to Top | Article Outline

The HOPS Investigators include the following investigators and sites: Anne C. Moorman, Tony Tong, Scott D. Holmberg (currently at Research Triangle Institute, Atlanta), John T. Brooks, and Kate Buchacz, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA; Kathleen C. Wood, Rose K. Baker, and Carl Armon, Cerner Corporation, Vienna, VA; Frank J. Palella, Joan S. Chmiel, Katharine A. Kirby, Janet Cheley, and Tiffany Murphy, Feinberg School of Medicine, Northwestern University, Chicago, IL; Kenneth A. Lichtenstein, University of Colorado Health Sciences Center, Denver, CO; Kenneth S. Greenberg, Benjamin Young, Barbara Widick, Cheryl Stewart, and Peggy Zellner, Rose Medical Center, Denver, CO; Bienvenido G. Yangco, Kalliope Halkias, and Arletis Lay, Infectious Disease Research Institute, Tampa, FL; Douglas J. Ward and Charles A. Owen, Dupont Circle Physicians Group, Washington, DC; Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, and Jane Esteves, State University of New York, Stony Brook, NY; Ellen M. Tedaldi, Ramona A. Christian, and Linda Walker-Kornegay, Temple University School of Medicine, Philadelphia, PA; Joseph B. Marzouk, Roger T. Phelps, and Mark Rachel, Adult Immunology Clinic, Oakland, CA; Silver Sisneros and Mark Rachel, Fairmont Hospital, San Leandro, CA; Richard M. Novak, Jonathan P. Uy, and Andrea Wendrow, University of Illinois at Chicago, Chicago, IL.

Cited By:

This article has been cited 217 time(s).

Critical Reviews in Immunology
Dimethyl Fumarate Modulation of Immune and Antioxidant Responses: Application to HIV Therapy
Gill, AJ; Kolson, DL
Critical Reviews in Immunology, 33(4): 307-359.

Journal of Infection in Developing Countries
Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time?
Socias, ME; Rotryng, F; Lapadula, P; Medrano, M; Paz, D; Stern, L; Lambierto, A; Pryluka, D
Journal of Infection in Developing Countries, 7(8): 593-599.
European Review for Medical and Pharmacological Sciences
High prevalence of undiagnosed anxiety symptoms among HIV-positive individuals on cART: a cross-sectional study
Celesia, BM; Nigro, L; Pinzone, MR; Coco, C; La Rosa, R; Bisicchia, F; Mavilla, S; Gussio, M; Pellicano, G; Milioni, V; Palermo, F; Russo, R; Mughini, MT; Martellotta, F; Taibi, R; Cacopardo, B; Nunnari, G
European Review for Medical and Pharmacological Sciences, 17(): 2040-2046.

European Review for Medical and Pharmacological Sciences
Kaposi's sarcoma in HIV-positive patients: the state of art in the HAART-era
La Ferla, L; Pinzone, MR; Nunnari, G; Martellotta, F; Lleshi, A; Tirelli, U; De Paoli, P; Berretta, M; Cacopardo, B
European Review for Medical and Pharmacological Sciences, 17(): 2354-2365.

Hepatology Research
Detection of highly prevalent hepatitis B virus co-infection with HIV in Indonesia
Utsumi, T; Yano, Y; Lusida, MI; Nasronudin; Amin, M; Juniastuti; Soetjipto; Hotta, H; Hayashi, Y
Hepatology Research, 43(): 1032-1039.
Lancet Infectious Diseases
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1
Whitaker, JA; Rouphael, NG; Edupuganti, S; Lai, LL; Mulligan, MJ
Lancet Infectious Diseases, 12(): 966-976.

Cold Spring Harbor Perspectives in Medicine
HIV Pathogenesis: The Host
Lackner, AA; Lederman, MM; Rodriguez, B
Cold Spring Harbor Perspectives in Medicine, 2(9): -.
ARTN a007005
AIDS Research and Human Retroviruses
Persistently Elevated Serum Interleukin-6 Predicts Mortality Among Adults Receiving Combination Antiretroviral Therapy in Botswana: Results from a Clinical Trial
McDonald, B; Moyo, S; Gabaitiri, L; Gaseitsiwe, S; Bussmann, H; Koethe, JR; Musonda, R; Makhema, J; Novitsky, V; Marlink, RG; Wester, CW; Essex, M
AIDS Research and Human Retroviruses, 29(7): 993-999.
Bmc Infectious Diseases
All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010
Hernando, V; Alejos, B; Monge, S; Berenguer, J; Anta, L; Vinuesa, D; Palacios, R; Muga, R; Moreno, S; Jarrin, I
Bmc Infectious Diseases, 13(): -.
ARTN 382
AIDS Patient Care and Stds
Thromboses among HIV-Infected Patients during the Highly Active Antiretroviral Therapy Era
Crum-Cianflone, NF; Weekes, J; Bavaro, M
AIDS Patient Care and Stds, 22(): 771-778.
Archives of Pediatrics & Adolescent Medicine
Incidence of Noninfectious Conditions in Perinatally HIV-Infected Children and Adolescents in The HAART Era
Nachman, SA; Chernoff, M; Gona, P; Van Dyke, RB; Dankner, WM; Seage, GR; Oleske, J; Williams, PL
Archives of Pediatrics & Adolescent Medicine, 163(2): 164-171.

Cytometry Part B-Clinical Cytometry
Assessment of Mitochondrial Toxicity by Analysis of Mitochondrial Protein Expression in Mononuclear Cells
Lin, CH; Sloan, DD; Dang, CH; Wagner, T; Cabrera, AJE; Tobin, NH; Frenkel, LM; Jerome, KR
Cytometry Part B-Clinical Cytometry, 76B(3): 181-190.
HIV Medicine
Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease
Grau, I; Ardanuy, C; Linares, J; Podzamczer, D; Schulze, MH; Pallares, R
HIV Medicine, 10(8): 488-495.
Risk Factors and Clinical Characteristics Associated with Hospitalization for Community-Acquired Bacterial Pneumonia in HIV-Positive Patients According to the Presence of Liver Cirrhosis
Manno, D; Puoti, M; Signorini, L; Lapadula, G; Cadeo, B; Soavi, L; Paraninfo, G; Allegri, R; Cristini, G; Viale, P; Carosi, G
Infection, 37(4): 334-339.
HIV Medicine
Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers
Justice, AC; McGinnis, KA; Skanderson, M; Chang, CC; Gibert, CL; Goetz, MB; Rimland, D; Rodriguez-Barradas, MC; Oursler, KK; Brown, ST; Braithwaite, RS; May, M; Covinsky, KE; Roberts, MS; Fultz, SL; Bryant, KJ
HIV Medicine, 11(2): 143-151.
HIV Medicine
Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the MortalitE 2005 survey, ANRS EN19)
Rosenthal, E; Salmon-Ceron, D; Lewden, C; Bouteloup, V; Pialoux, G; Bonnet, F; Karmochkine, M; May, T; Francois, M; Burty, C; Jougla, E; Costagliola, D; Morlat, P; Chene, G; Cacoub, P
HIV Medicine, 10(5): 282-289.
Bulletin of the World Health Organization
Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa
Herbst, AJ; Cooke, GS; Barnighausen, T; KanyKany, A; Tanser, F; Newell, ML
Bulletin of the World Health Organization, 87(): 754-762.
Journal of Hepatology
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study
Salmon-Ceron, D; Rosenthal, E; Lewden, C; Bouteloup, V; May, T; Burty, C; Bonnet, F; Costagliola, D; Jougla, E; Semaille, C; Morlat, P; Cacoub, P; Chene, G
Journal of Hepatology, 50(4): 736-745.
Bmc Infectious Diseases
Improvement in survival among HIV-infected individuals in the Republic of Korea: Need for an early HIV diagnosis
Kee, MK; Lee, JH; Kim, EJ; Lee, J; Nam, JG; Yoo, BH; Kim, SS
Bmc Infectious Diseases, 9(): -.
ARTN 128
Journal of the National Medical Association
Disparities in Antiretroviral Prescribing for Blacks and Whites in the United States
Oramasionwu, CU; Skinner, J; Ryan, L; Frei, CR
Journal of the National Medical Association, 101(): 1140-1144.

Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
Else, L; Watson, V; Tjia, J; Hughes, A; Siccardi, M; Khoo, S; Back, D
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 878(): 1455-1465.
Gastrointestinal complications of HIV infection: changing priorities in the HAART era
Wilcox, CM; Saag, MS
Gut, 57(6): 861-870.
AIDS Reader
Highlights of a year in AIDS
Laurence, J
AIDS Reader, 17(3): 107-+.

International Journal of Drug Policy
HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management
Lazarus, JV; Shete, PB; Eramova, I; Merkinaite, S; Matic, S
International Journal of Drug Policy, 18(5): 426-432.
Clinical and Experimental Rheumatology
HIV/AIDS: epidemic update, new treatment strategies and impact on autoimmunity
Croce, F; Piconi, S; Atzeni, F; Sarzi-Puttini, P; Galli, M; Clerici, M
Clinical and Experimental Rheumatology, 26(1): S48-S52.

HIV Medicine
Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005
Yang, CH; Huang, YF; Hsiao, CF; Yeh, YL; Liou, HR; Hung, CC; Yang, SY
HIV Medicine, 9(7): 535-543.
Clinical Infectious Diseases
Changes in Cancer Mortality among HIV-Infected Patients: The Mortalite 2005 Survey
Bonnet, F; Burty, C; Lewden, C; Costagliola, D; May, T; Bouteloup, V; Rosenthal, E; Jougla, E; Cacoub, P; Salmon, D; Chene, G; Morlat, P
Clinical Infectious Diseases, 48(5): 633-639.
Cadernos De Saude Publica
The first ten years: achievements and challenges of the Brazilian program of universal access to HIV/AIDS comprehensive management and care, 1996-2006
Hacker, MA; Kaida, A; Hogg, RS; Bastos, FI
Cadernos De Saude Publica, 23(): S345-S359.

Digestive Diseases and Sciences
An overview of HIV and chronic viral hepatitis co-infection
Cooper, CL
Digestive Diseases and Sciences, 53(4): 899-904.
Bmc Infectious Diseases
Black race as a predictor of poor health outcomes among a national cohort of HIV/AIDS patients admitted to US hospitals: a cohort study
Oramasionwu, CU; Hunter, JM; Skinner, J; Ryan, L; Lawson, KA; Brown, CM; Makos, BR; Frei, CR
Bmc Infectious Diseases, 9(): -.
ARTN 127
Current HIV Research
Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study
Baxter, JD; Bhatti, L; Coakley, E; Bartczak, J; McDonough, M; Vinisko, R; Piliero, PJ
Current HIV Research, 8(4): 347-354.

Plos One
Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in Brazil
Pacheco, AG; Tuboi, SH; Faulhaber, JC; Harrison, LH; Schechter, M
Plos One, 3(1): -.
ARTN e1531
Clinical Infectious Diseases
Missed Visits and Mortality among Patients Establishing Initial Outpatient HIV Treatment
Mugavero, MJ; Lin, HY; Willig, JH; Westfall, AO; Ulett, KB; Routman, JS; Abroms, S; Raper, JL; Saag, MS; Allison, JJ
Clinical Infectious Diseases, 48(2): 248-256.
American Journal of Epidemiology
The Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN Study)
Vellozzi, C; Brooks, JT; Bush, TJ; Conley, LJ; Henry, K; Carpenter, CCJ; Overton, ET; Hammer, J; Wood, K; Holmberg, SD
American Journal of Epidemiology, 169(5): 642-652.
AIDS Patient Care and Stds
Genital and Perianal Herpes Simplex Simulating Neoplasia in Patients with AIDS
Mosunjac, M; Park, J; Wang, W; Tadros, T; Siddiqui, M; Bagirov, M; Little, J
AIDS Patient Care and Stds, 23(3): 153-158.
New England Journal of Medicine
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, MM; Gange, SJ; Abraham, AG; Merriman, B; Saag, MS; Justice, AC; Hogg, RS; Deeks, SG; Eron, JJ; Brooks, JT; Rourke, SB; Gill, MJ; Bosch, RJ; Martin, JN; Klein, MB; Jacobson, LP; Rodriguez, B; Sterling, TR; Kirk, GD; Napravnik, S; Rachlis, AR; Calzavara, LM; Horberg, MA; Silverberg, MJ; Gebo, KA; Goedert, JJ; Benson, CA; Collier, AC; Van Rompaey, SE; Crane, HM; McKaig, RG; Lau, B; Freeman, AM; Moore, RD
New England Journal of Medicine, 360(): 1815-1826.
International Journal of Infectious Diseases
Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa
Cooper, CL; Mills, E; Wabwire, BO; Ford, N; Olupot-Olupot, P
International Journal of Infectious Diseases, 13(3): 302-306.
Janac-Journal of the Association of Nurses in AIDS Care
Process and contents of telephone consultations between registered nurses and clients with HIV/AIDS in Japan
Nishigaki, M; Shimada, M; Ikeda, K; Kazuma, K; Ogane, M; Takeda, K; Yamada, Y; Fukuyama, Y; Ito, S; Kishigami, F; Kimura, S
Janac-Journal of the Association of Nurses in AIDS Care, 18(6): 85-96.
Clinical Infectious Diseases
The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China
Zhang, FJ; Dou, ZH; Yu, L; Xu, JH; Jiao, JH; Wang, N; Ma, Y; Zhao, Y; Zhao, HX; Chen, RY
Clinical Infectious Diseases, 47(6): 825-833.
Clinical Infectious Diseases
Rate of comorbidities not related to HIV infection or AIDS among HIV infected patients, by CD4 cell count and HAART use status
Moore, RD; Gebo, KA; Lucas, GM; Keruly, JC
Clinical Infectious Diseases, 47(8): 1102-1104.
Clinical Infectious Diseases
Hospitalization for Pneumonia among Individuals With and Without HIV Infection, 1995-2007: A Danish Population-Based, Nationwide Cohort Study
Sogaard, OS; Lohse, N; Gerstoft, J; Kronborg, G; Ostergaard, L; Pedersen, C; Pedersen, G; Sorensen, HT; Obel, N
Clinical Infectious Diseases, 47(): 1345-1353.
AIDS Reader
HIV-Related Lipodystrophy in Africa and Asia
Womack, J
AIDS Reader, 19(4): 131-+.

AIDS Education and Prevention
Review: the Need for Smoking Cessation Among HIV-Positive Smokers
Nahvi, S; Cooperman, NA
AIDS Education and Prevention, 21(3): 14-27.

AIDS Patient Care and Stds
Race, Outpatient Mental Health Service Use, and Survival After an AIDS Diagnosis in the Highly Active Antiretroviral Therapy Era
Mkanta, WN; Mejia, MC; Duncan, RP
AIDS Patient Care and Stds, 24(1): 31-37.
Journal of Neurovirology
Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain
Lamers, SL; Salemi, M; Galligan, DC; Morris, A; Gray, R; Fogel, G; Zhao, L; McGrath, MS
Journal of Neurovirology, 16(3): 230-241.
Trends in perimortal conditions and mortality rates among HIV-infected patients
Hooshyar, D; Hanson, DL; Wolfe, M; Selik, RM; Buskin, SE; McNaghten, AD
AIDS, 21(): 2093-2100.

American Journal of Psychiatry
Relation of lifetime trauma and depressive symptoms to mortality in HIV
Leserman, J; Pence, BW; Whetten, K; Mugavero, MJ; Thielman, NM; Swartz, MS; Stangl, D
American Journal of Psychiatry, 164(): 1707-1713.
British Journal of Clinical Pharmacology
Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study
Mehta, U; Durrheim, DN; Blockman, M; Kredo, T; Gounden, R; Barnes, KI
British Journal of Clinical Pharmacology, 65(3): 396-406.
HIV Clinical Trials
Determination of the underlying cause of death in three multicenter international HIV clinical trials
Lifson, AR; Belloso, WH; Carey, C; Davey, RT; Duprez, D; El-Sadr, WM; Gatell, JM; Gey, DC; Hoy, JF; Krum, EA; Nelson, R; Nixon, DE; Paton, N; Pedersen, C; Perez, G; Price, RW; Prineas, RJ; Rhame, FS; Sampson, J; Worley, J
HIV Clinical Trials, 9(3): 177-185.
Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005
Buchacz, K; Baker, RK; Moorman, AC; Richardson, JT; Wood, KC; Holmberg, SD; Brooks, JT
AIDS, 22(): 1345-1354.

Human Vaccines
Attitudes towards vaccines and infectious disease risk among U. S. troops
Porter, CK; Bowens, MJ; Tribble, DR; Putnam, SD; Sanders, JW; Riddle, MS
Human Vaccines, 4(4): 298-304.

Journal of Managed Care Pharmacy
The HIV landscape in a managed care environment: Current challenges and potential solutions
Chao, SH
Journal of Managed Care Pharmacy, 12(7): S2-S5.

Medizinische Klinik
HIV infection 2007
Potthoff, A; Brockmeyer, N
Medizinische Klinik, 102(7): 531-539.
Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver
Desai, VG; Lee, T; Delongchamp, RR; Leakey, JEA; Lewis, SM; Lee, F; Moland, CL; Branham, WS; Fuscoe, JC
Mitochondrion, 8(2): 181-195.
Plos One
Extensive HIV-1 Intra-Host Recombination Is Common in Tissues with Abnormal Histopathology
Lamers, SL; Salemi, M; Galligan, DC; de Oliveira, T; Fogel, GB; Granier, SC; Zhao, L; Brown, JN; Morris, A; Masliah, E; McGrath, MS
Plos One, 4(3): -.
ARTN e5065
Science in China Series C-Life Sciences
High level HIV-1 DNA concentrations in brain tissues differentiate patients with post-HAART AIDS dementia complex or cardiovascular disease from those with AIDS
Zhao, L; Galligan, DC; Lamers, SL; Yu, S; Shagrun, L; Salemi, M; McGrath, MS
Science in China Series C-Life Sciences, 52(7): 651-656.
AIDS Patient Care and Stds
Prevalence and Impact of Body Physical Changes in HIV Patients Treated with Highly Active Antiretroviral Therapy: Results from a Study on Patient and Physician Perceptions
Cabrero, E; Griffa, L; Burgos, A
AIDS Patient Care and Stds, 24(1): 5-13.
HIV Medicine
Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy
Grabar, S; Lanoy, E; Allavena, C; Mary-Krause, M; Bentata, M; Fischer, P; Mahamat, A; Rabaud, C; Costagliola, D
HIV Medicine, 9(4): 246-256.
Clinical Infectious Diseases
HIV care and the incidence of acute renal failure
Roe, J; Campbell, LJ; Ibrahim, F; Hendry, BM; Post, FA
Clinical Infectious Diseases, 47(2): 242-249.
Journal of Managed Care Pharmacy
Strategies to enhance adherence, reduce costs, and improve patient quality of life
McNicholl, IR
Journal of Managed Care Pharmacy, 14(5): S12-S16.

Journal of Infection
Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients
BadioU, S; Thiebaut, R; Aurillac-Lavignolle, V; Dabis, F; Laporte, F; Cristol, JP; Mercie, P
Journal of Infection, 57(1): 47-54.
Pharmacogenetics of tenofovir treatment
Rodriguez-Novoa, S; Labarga, P; Soriano, V
Pharmacogenomics, 10(): 1675-1685.
Clinical Infectious Diseases
AIDS Drug Assistance Programs in the era of routine HIV testing
Bassett, IV; Farel, C; Szmuilowicz, ED; Walensky, RP
Clinical Infectious Diseases, 47(5): 695-701.
Clinical Infectious Diseases
Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non-Subtype B HIV-1
Pond, SLK; Smith, DM
Clinical Infectious Diseases, 48(9): 1306-1309.
Medicina Clinica
Neoplasms and HIV in the epidemic's third decade
Santos, J
Medicina Clinica, 133(): 750-751.
AIDS Reviews
Strategies to Optimize HIV Treatment Outcomes in Resource-Limited Settings
Nakanjako, D; Colebunders, R; Coutinho, AG; Kamya, MR
AIDS Reviews, 11(4): 179-189.

International Journal of Infectious Diseases
Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India
Kumarasamy, N; Venkatesh, KK; Devaleenol, B; Poongulali, S; Yephthomi, T; Pradeep, A; Saghayam, S; Flanigan, T; Mayer, KH; Solomon, S
International Journal of Infectious Diseases, 14(2): E127-E131.
Journal of Infectious Diseases
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults
Dunn, D; Woodburn, P; Duong, T; Peto, J; Phillips, A; Gibb, D; Porter, K
Journal of Infectious Diseases, 197(3): 398-404.
Cadernos De Saude Publica
AIDS mortality, "race or color", and social inequality in a context of universal access to highly active antiretroviral therapy (HAART) in Brazil, 1999-2004
Fonseca, MGP; Lucena, FDA; de Sousa, A; Bastos, FI
Cadernos De Saude Publica, 23(): S445-S455.

Antiviral Therapy
Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men
He, Q; Engelson, ES; Ionescu, G; Glesby, MJ; Albu, JB; Kotler, DP
Antiviral Therapy, 13(3): 423-428.

Clinical Medicine
National review of deaths among HIV-infected adults
Lucas, SB; Curtis, H; Johnson, MA
Clinical Medicine, 8(3): 250-252.

Ciencia & Saude Coletiva
"Get back to where you once belonged": monitoring the AIDS pandemic in the 21st century
Bastos, FI
Ciencia & Saude Coletiva, 13(6): 1719-1727.

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Na < ve to Antiretroviral Therapy
Antinori, A; Ammassari, A; Torti, C; Marconi, P; Andreoni, M; Angarano, G; Bonora, S; Castagna, A; Cauda, R; Clerici, M; Monforte, AD; De Luca, A; Di Perri, G; Galli, M; Girardi, E; Gori, A; Lazzarin, A; Lo Caputo, S; Mazzotta, F; Montella, F; Mussini, C; Perno, CF; Puoti, M; Rizzardini, G; Rusconi, S; Vullo, V; Carosi, G
Infection, 37(3): 270-282.
Journal of Antimicrobial Chemotherapy
HIV/hepatitis B virus co-infection: current challenges and new strategies
Lacombe, K; Bottero, J; Lemoine, M; Boyd, A; Girard, PM
Journal of Antimicrobial Chemotherapy, 65(1): 10-17.
Journal of the National Medical Association
HIV/AIDS Disparities: The Mounting Epidemic Plaguing US Blacks
Oramasionwu, CU; Brown, CM; Ryan, L; Lawson, KA; Hunter, JM; Frei, CR
Journal of the National Medical Association, 101(): 1196-1204.

Emergency Medicine Clinics of North America
Metabolic and Hepatobiliary Side Effects of Antiretroviral Therapy (ART)
Lugassy, DM; Farmer, BM; Nelson, LS
Emergency Medicine Clinics of North America, 28(2): 409-+.
Clinics in Chest Medicine
Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome and Unmasking of Tuberculosis by Antiretroviral Therapy
Meintjes, G; Rabie, H; Wilkinson, RJ; Cotton, MF
Clinics in Chest Medicine, 30(4): 797-+.
Longitudinal study of the ocular complications of AIDS - 1. Ocular diagnoses at enrollment
Jabs, DA; Van Natta, ML; Holbrook, JT; Kempen, JH; Meinert, CL; Davis, MD
Ophthalmology, 114(4): 780-786.
Transactions of the Royal Society of Tropical Medicine and Hygiene
Declining incidence of intestinal microsporidiosis and reduction in AIDS-related mortality following introduction of HAART in Sydney, Australia
van Hal, SJ; Muthiah, K; Matthews, G; Harkness, J; Stark, D; Cooper, D; Marriott, D
Transactions of the Royal Society of Tropical Medicine and Hygiene, 101(): 1096-1100.
Journal of Medicinal Chemistry
Design and synthesis of human immunodeficiency virus entry inhibitors: Sulfonamide as an isostere for the alpha-ketoamide group
Lu, RJ; Tucker, JA; Zinevitch, T; Kirichenko, O; Konoplev, V; Kuznetsova, S; Sviridov, S; Pickens, J; Tandel, S; Brahmachary, E; Yang, Y; Wang, J; Freel, S; Fisher, S; Sullivan, A; Zhou, J; Stanfield-Oakley, S; Greenberg, M; Bolognesi, D; Bray, B; Koszalka, B; Jeffs, P; Khasanov, A; Ma, YA; Jeffries, C; Liu, C; Proskurina, T; Zhu, T; Chucholowski, A; Li, R; Sexton, C
Journal of Medicinal Chemistry, 50(): 6535-6544.
AIDS Reader
Non-AIDS-defining cancers: Should antiretroviral therapy be initiated earlier?
Cinti, SK; Gandhi, T; Riddell, J
AIDS Reader, 18(1): 18-+.

Postgraduate Medicine
Diagnosis and Management of Common Chronic Metabolic Complications in HIV-Infected Patients
Bader, MS; Kelly, DV
Postgraduate Medicine, 120(4): 17-27.

Plos One
Interactive "Video Doctor" Counseling Reduces Drug and Sexual Risk Behaviors among HIV-Positive Patients in Diverse Outpatient Settings
Gilbert, P; Ciccarone, D; Gansky, SA; Bangsberg, DR; Clanon, K; McPhee, SJ; Calderon, SH; Bogetz, A; Gerbert, B
Plos One, 3(4): -.
ARTN e1988
European Journal of Medical Research
Switch From A Zdv/3Tc-Based Regimen to A Completely Once Daily (Qd) Regimen of Emtricitabine/Tenofovir Df Fixed Dose Combination Plus A Third Qd Agent (Sonett)
Arasteh, K; Weitner, L; Fenske, S; Kuhlmann, B; Freiwald, M; Ebrahimi, R; Gallo, L; Ranneberg, B; Mertenskoetter, T
European Journal of Medical Research, 14(5): 195-199.

Current HIV Research
The Changing Face of HIV/AIDS in Treated Patients
Llibre, JM; Falco, V; Tural, C; Negredo, E; Pineda, JA; Munoz, J; Ortega, E; Videla, S; Sirera, G; Martinez, E; Miralles, C; Iribarren, J; Galindo, MJ; Domingo, P; d'Arminio-Monforte, A; Miro, JM; Clotet, B
Current HIV Research, 7(4): 365-377.

American Journal of Epidemiology
Copy-Years Viremia as a Measure of Cumulative Human Immunodeficiency Virus Viral Burden
Cole, SR; Napravnik, S; Mugavero, MJ; Lau, B; Eron, JJ; Saag, MS
American Journal of Epidemiology, 171(2): 198-205.
Clinical Infectious Diseases
Transmission of HIV-1 Drug-Resistant Variants: Prevalence and Effect on Treatment Outcome
Jakobsen, MR; Tolstrup, M; Sogaard, OS; Jorgensen, LB; Gorry, PR; Laursen, A; Ostergaard, L
Clinical Infectious Diseases, 50(4): 566-573.
Social Science & Medicine
Race, place and AIDS: The role of socioeconomic context on racial disparities in treatment and survival in San Francisco
Arnold, M; Hsu, L; Pipkin, S; McFarland, W; Rutherford, GW
Social Science & Medicine, 69(1): 121-128.
Journal of Medicinal Chemistry
Heterobiaryl Human Immunodeficiency Virus Entry Inhibitors
Lu, RJ; Tucker, JA; Pickens, J; Ma, YA; Zinevitch, T; Kirichenko, O; Konoplev, V; Kuznetsova, S; Sviridov, S; Brahmachary, E; Khasanov, A; Mikel, C; Yang, Y; Liu, CH; Wang, J; Freel, S; Fisher, S; Sullivan, A; Zhou, JY; Stanfield-Oakley, S; Baker, B; Sailstad, J; Greenberg, M; Bolognesi, D; Bray, B; Koszalka, B; Jeffs, P; Jeffries, C; Chucholowski, A; Sexton, C
Journal of Medicinal Chemistry, 52(): 4481-4487.
International Journal of Epidemiology
Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalite 2000 & 2005' Surveys (ANRS EN19)
Hessamfar-Bonarek, M; Morlat, P; Salmon, D; Cacoub, P; May, T; Bonnet, F; Rosenthal, E; Costagliola, D; Lewden, C; Chene, G
International Journal of Epidemiology, 39(1): 135-146.
Cadernos De Saude Publica
Twenty-five years of the AIDS epidemic in Brazil: principal epidemiological findings, 1980-2005
Fonseca, MGP; Bastos, FI
Cadernos De Saude Publica, 23(): S333-S344.

Clinical Infectious Diseases
Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin
Martin-Carbonero, L; Palacios, R; Valencia, E; Saballs, P; Sirera, G; Santos, I; Baldobi, F; Alegre, M; Goyenechea, A; Pedreira, J; del Castillo, JG; Martinez-Lacasa, J; Ocampo, A; Alsina, M; Santos, J; Podzamczer, D; Gonzalez-Lahoz, J
Clinical Infectious Diseases, 47(3): 410-417.
Expert Opinion on Pharmacotherapy
Access denied? The status of co-receptor inhibition to counter HIV entry
Biswas, P; Tambussi, G; Lazzarin, A
Expert Opinion on Pharmacotherapy, 8(7): 923-933.
Future Virology
Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile
Gianotti, N; Lazzarin, A
Future Virology, 2(2): 131-143.
Journal of Medical Virology
Current HIV epidemiology and revised recommendations for HIV testing in health-care settings
Branson, B
Journal of Medical Virology, 79(): S6-S10.
Clinical Pharmacokinetics
Drug interactions between HIV protease inhibitors and acid-reducing agents
Falcon, RW; Kakuda, TN
Clinical Pharmacokinetics, 47(2): 75-89.

AIDS Reader
Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients
Doward, LC; Dietz, B; Wilburn, J; McKenna, SR; Bhor, M; Rajagopalan, R
AIDS Reader, 18(5): 242-+.

Hepatitis B and Human Immunodeficiency Virus Coinfection
Thio, CL
Hepatology, 49(5): S138-S145.
American Journal of Transplantation
Successful Lung Transplantation in an HIV- and HBV-Positive Patient with Cystic Fibrosis
Bertani, A; Grossi, P; Vitulo, P; D'Ancona, G; Arcadipane, A; Costa, AN; Gridelli, B
American Journal of Transplantation, 9(9): 2190-2196.
HIV Clinical Trials
Cost-effectiveness of Raltegravir in Antiretroviral Treatment-Experienced HIV-1-Infected Patients in Switzerland
Elbasha, EE; Szucs, T; Chaudhary, MA; Kumar, RN; Roediger, A; Cook, JR; Opravil, M
HIV Clinical Trials, 10(4): 233-253.
AIDS Patient Care and Stds
High-Volume Rapid HIV Testing in an Urban Emergency Department
Calderon, Y; Leider, J; Hailpern, S; Chin, R; Ghosh, R; Fettig, J; Gennis, P; Bijur, P; Bauman, L
AIDS Patient Care and Stds, 23(9): 749-757.
AIDS Research and Human Retroviruses
Predictors of Success with Highly Active Antiretroviral Therapy in an Antiretroviral-Naive Urban Population
Zaragoza-Macias, E; Cosco, D; Nguyen, ML; del Rio, C; Lennox, J
AIDS Research and Human Retroviruses, 26(2): 133-138.
AIDS Patient Care and Stds
The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS
Vidrine, DJ; Arduino, RC; Gritz, ER
AIDS Patient Care and Stds, 21(9): 659-666.
Seminars in Nephrology
Acute Kidney Injury in HIV-Infected Patients
Kalim, S; Szczech, LA; Wyatt, CM
Seminars in Nephrology, 28(6): 556-562.
Journal of Antimicrobial Chemotherapy
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C
Meynard, JL; Lacombe, K; Poirier, JM; Legrand, J; Morand-Joubert, L; Girard, PM
Journal of Antimicrobial Chemotherapy, 63(3): 579-584.
Canadian Journal of Infectious Diseases & Medical Microbiology
Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre
Brassard, P; Hottes, TS; Lalonde, RG; Klein, MB
Canadian Journal of Infectious Diseases & Medical Microbiology, 20(2): 51-57.

Plos One
Fertility Desires and Intentions of HIV-Positive Women of Reproductive Age in Ontario, Canada: A Cross-Sectional Study
Loutfy, MR; Hart, TA; Mohammed, SS; Su, DS; Ralph, ED; Walmsley, SL; Soje, LC; Muchenje, M; Rachlis, AR; Smaill, FM; Angel, JB; Raboud, JM; Silverman, MS; Tharao, WE; Gough, K; Yudin, MH
Plos One, 4(): -.
ARTN e7925
AIDS Patient Care and Stds
Integrating Smoking Cessation into HIV Care
Drach, L; Holbert, T; Maher, J; Fox, V; Schubert, S; Saddler, LC
AIDS Patient Care and Stds, 24(3): 139-140.
Clinical Infectious Diseases
Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies
Gill, J; May, M; Lewden, C; Saag, M; Mugavero, M; Reiss, P; Ledergerber, B; Mocroft, A; Harris, R; Fux, CA; Justice, A; Costagliola, D; Casabona, J; Hogg, RS; Khaykin, P; Lampe, F; Vehreschild, J; Sterne, JAC; Egger, M; Brodt, HR; Casabona, J; Chene, G; Costagliola, D; Dabis, F; Monforte, AD; de Wolf, F; Fatkenheuer, G; Gill, J; Guest, J; Hogg, RS; Justice, A; Kirk, O; Kitahata, M; Lampe, F; Ledergerber, B; Reiss, P; Sterling, T
Clinical Infectious Diseases, 50(): 1387-1396.
Emergency Medicine Clinics of North America
Renal and Urologic Emergencies in the HIV-infected Patient
Liang, SY; Overton, ET
Emergency Medicine Clinics of North America, 28(2): 343-+.
Deutsche Medizinische Wochenschrift
Wasmuth, JC; Rockstroh, JK
Deutsche Medizinische Wochenschrift, 132(): 673-683.
Revista DO Instituto De Medicina Tropical De Sao Paulo
Clinical and histological characteristics of HIV and hepatitis C virus-co-infected patients in Brazil: A case series study
Mendes-Correa, MC; Widman, A; Brussi, MLP; Guastini, CF; Cavalheiro, ND; Melo, CE; Barone, AA; Gianini, RJ
Revista DO Instituto De Medicina Tropical De Sao Paulo, 50(4): 213-217.

Chinese Medical Journal
Improving China's antiretroviral treatment program: assessing current and future performance using the principals of ethics
Yin, WY; Zhang, FJ; Juniper, N; Wu, ZY
Chinese Medical Journal, 122(): 1346-1351.
Journal of the American Geriatrics Society
Prediction of Cardiorespiratory Fitness in Older Men Infected with the Human Immunodeficiency Virus: Clinical Factors and Value of the Six-Minute Walk Distance
Oursler, KK; Katzel, LI; Smith, BA; Scott, WB; Russ, DW; Sorkin, JD
Journal of the American Geriatrics Society, 57(): 2055-2061.
Reviews in Medical Virology
Solid organ transplantation in HIV-infected individuals: an update
Huprikar, S
Reviews in Medical Virology, 19(6): 317-323.
Clinical Infectious Diseases
Human T lymphotropic virus type 1 - Associated myelopathy/tropical spastic paraparesis in an HIV-Positive patient coinfected with human T lymphotropic virus type 2 following initiation of Antiretroviral therapy
Toro, C; Blanco, F; Garcia-Gasco, P; Sheldon, J; Benito, JM; Rallon, NI; Soriano, V
Clinical Infectious Diseases, 45(9): E118-E120.
Clinical Infectious Diseases
Universal HIV testing: Is it enough?
Goicoechea, M; Smith, DM
Clinical Infectious Diseases, 45(): 1375-1376.
AIDS Patient Care and Stds
Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil
Mendes-Correa, MC; Widman, A; Brussi, MLP; Guastini, CF; Gianini, RJ
AIDS Patient Care and Stds, 22(9): 701-707.
Annals of Pharmacotherapy
Integrase Inhibitors: A Novel Class of Antiretroviral Agents
Schafer, JJ; Squires, KE
Annals of Pharmacotherapy, 44(1): 145-156.
Plos One
Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial
Zolopa, AR; Andersen, J; Komarow, L; Sanne, I; Sanchez, A; Hogg, E; Suckow, C; Powderly, W
Plos One, 4(5): -.
ARTN e5575
HIV Medicine
Cryptogenic liver disease in HIV-seropositive men
Dinh, MH; Stosor, V; Rao, SM; Miller, FH; Green, RM
HIV Medicine, 10(7): 447-453.
AIDS Research and Human Retroviruses
Cost-Effectiveness Analysis of Raltegravir in Treatment-Experienced HIV Type 1-Infected Patients in Spain
Chaudhary, MA; Moreno, S; Kumar, RN; Nocea, G; Elbasha, E
AIDS Research and Human Retroviruses, 25(7): 679-689.
AIDS Patient Care and Stds
Prevalence and Factors Associated with Renal Dysfunction Among HIV-Infected Patients
Crum-Cianflone, N; Ganesan, A; Teneza-Mora, N; Riddle, M; Medina, S; Barahona, I; Brodine, S
AIDS Patient Care and Stds, 24(6): 353-360.
International Review of Psychiatry
Treatment of depression in HIV positive individuals: A critical review
Ferrando, SJ; Freyberg, Z
International Review of Psychiatry, 20(1): 61-71.
HIV Medicine
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study
Squillace, N; Lapadula, G; Torti, C; Orlando, G; Mandalia, S; Nardini, G; Beghetto, B; Costarelli, S; Guaraldi, G
HIV Medicine, 9(3): 151-159.
Clinical Pharmacology & Therapeutics
Lopinavir-Ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma
Corona, G; Vaccher, E; Sandron, S; Sartor, I; Tirelli, U; Innocenti, F; Toffoli, G
Clinical Pharmacology & Therapeutics, 83(4): 601-606.
Jama-Journal of the American Medical Association
Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel
Hammer, SM; Eron, JJ; Reiss, P; Schooley, RT; Thompson, MA; Walmsley, S; Cahn, P; Fischl, MA; Gatell, JM; Hirsch, MS; Jacobsen, DM; Montaner, JSG; Richman, DD; Yeni, PG; Volberding, PA
Jama-Journal of the American Medical Association, 300(5): 555-570.

Brazilian Journal of Infectious Diseases
Survival of AIDS Patients and Characteristics of Those Who Died Over Eight Years of Highly Active Antiretroviral Therapy, at a Referral Center in Northeast Brazil
Santos, L; de Melo, W; Lacerda, HR; Campelo, E; Moraes, E; Ximenes, RAD
Brazilian Journal of Infectious Diseases, 12(4): 269-277.

Ciencia & Saude Coletiva
From "acute AIDS" to "chronic AIDS": body perception and surgical interventions in people living with HIV and AIDS
de Alencar, TM; Nemes, MIB; Velloso, MA
Ciencia & Saude Coletiva, 13(6): 1841-1849.

AIDS and Behavior
Depression Symptoms and Treatment Among HIV Infected and Uninfected Veterans
Sueoka, K; Goulet, JL; Fiellin, DA; Rimland, D; Butt, AA; Gibert, C; Rodriguez-Barradas, MC; Bryant, K; Crystal, S; Justice, AC
AIDS and Behavior, 14(2): 272-279.
HIV Medicine
Hospitalization risk following initiation of highly active antiretroviral therapy
Berry, SA; Manabe, YC; Moore, RD; Gebo, KA
HIV Medicine, 11(5): 289-298.
Clinical Gastroenterology and Hepatology
Prevalence and Factors Associated With Liver Test Abnormalities Among Human Immunodeficiency Virus-Infected Persons
Crum-Cianflone, N; Collins, G; Medina, S; Asher, D; Campin, R; Bavaro, M; Hale, B; Hames, C
Clinical Gastroenterology and Hepatology, 8(2): 183-191.
European Journal of Health Economics
Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain
Oliva-Moreno, J; Lopez-Bastida, J; Serrano-Aguilar, P; Perestelo-Perez, L
European Journal of Health Economics, 11(4): 405-412.
European Journal of Medicinal Chemistry
Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors
Ribone, SR; Leen, V; Madrid, M; Dehaen, W; Daelemans, D; Pannecouque, C; Brinon, MC
European Journal of Medicinal Chemistry, 58(): 485-492.
Archives of Internal Medicine
The Influence of Sex, Race/Ethnicity, and Educational Attainment on Human Immunodeficiency Virus Death Rates Among Adults, 1993-2007
Simard, EP; Fransua, M; Naishadham, D; Jemal, A
Archives of Internal Medicine, 172(): 1591-1598.
HIV Medicine
Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer
Simmons, RD; Ciancio, BC; Kall, MM; Rice, BD; Delpech, VC
HIV Medicine, 14(): 596-604.
HIV Medicine
Are neighborhood conditions associated with HIV management?
Shacham, E; Lian, M; Onen, NF; Donovan, M; Overton, ET
HIV Medicine, 14(): 624-632.
American Journal of Respiratory and Critical Care Medicine
Death in Pulmonary Arterial Hypertension
Oudiz, RJ
American Journal of Respiratory and Critical Care Medicine, 188(3): 269-270.
Brazilian Journal of Infectious Diseases
Aging with HIV: a practical review
Cardoso, SW; Torres, TS; Santini-Oliveira, M; Monteiro, L; Marins, S; Veloso, VG; Grinsztejn, B
Brazilian Journal of Infectious Diseases, 17(4): 464-479.
International Journal of Std & AIDS
Patterns and predictors of cigarette smoking among HIV-infected patients in northern Nigeria
Iliyasu, Z; Gajida, AU; Abubakar, IS; Shittu, O; Babashani, M; Aliyu, MH
International Journal of Std & AIDS, 23(): 849-852.
Plos One
Routine HIV Testing among Hospitalized Patients in Argentina. Is It Time for a Policy Change?
Socias, ME; Hermida, L; Singman, M; Kulgis, G; Armas, AD; Cando, O; Sued, O; Perez, H; Hermes, R; Presas, JL; Cahn, P
Plos One, 8(7): -.
ARTN e69517
HIV Medicine
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study
Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B
HIV Medicine, 14(4): 195-207.
Health Education & Behavior
At the Intersection of HIV/AIDS and Cancer: A Qualitative Needs Assessment of Community-Based HIV/AIDS Service Organizations
Burkhalter, JE; Cahill, S; Shuk, E; Guidry, J; Corner, G; Berk, A; Candelario, N; Kornegay, M; Lubetkin, EI
Health Education & Behavior, 40(4): 493-503.
Journal of Cardiothoracic and Vascular Anesthesia
The Patient With the Human Immunodeficiency Virus-1 in the Cardiovascular Operative Setting
Conte, AH; Esmailian, F; LaBounty, T; Lubin, L; Hardy, WD; Yumul, R
Journal of Cardiothoracic and Vascular Anesthesia, 27(1): 135-155.
AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV
Smoking cessation interventions with female smokers living with HIV/AIDS: A randomized pilot study of motivational interviewing
Manuel, JK; Lum, PJ; Hengl, NS; Sorensen, JL
AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV, 25(7): 820-827.
The contribution of HIV infection to intracranial arterial remodeling: A pilot study
Gutierrez, J; Elkind, MSV; Petito, C; Chung, DY; Dwork, AJ; Marshall, RS
Neuropathology, 33(3): 256-263.
Journal of the International AIDS Society
HIV and disability: a pilot study exploring the use of the Assessment of Motor and Process Skills to measure daily life performance
Merritt, B; Gahagan, J; Kottorp, A
Journal of the International AIDS Society, 16(): -.
ARTN 17339
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: A matched cohort study
Spagnuolo, V; Travi, G; Galli, L; Cossarini, F; Guffanti, M; Gianotti, N; Salpietro, S; Lazzarin, A; Castagna, A
Cancer, 119(): 2710-2719.
Plos One
Inflammation in HIV-Infected Patients: Impact of HIV, Lifestyle, Body Composition, and Demography - A Cross Sectional Cohort Study
Langkilde, A; Petersen, J; Klausen, HH; Henriksen, JH; Eugen-Olsen, J; Andersen, O
Plos One, 7(): -.
ARTN e51698
HIV Medicine
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients
Fabbiani, M; Ciccarelli, N; Tana, M; Farina, S; Baldonero, E; Di Cristo, V; Colafigli, M; Tamburrini, E; Cauda, R; Silveri, MC; Grima, P; Di Giambenedetto, S
HIV Medicine, 14(3): 136-144.
Drugs & Aging
The Next Therapeutic Challenge in HIV: Polypharmacy
Edelman, EJ; Gordon, KS; Glover, J; McNicholl, IR; Fiellin, DA; Justice, AC
Drugs & Aging, 30(8): 613-628.
Expert Opinion on Drug Safety
Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management
Fernandez-Montero, JV; Eugenia, E; Barreiro, P; Labarga, P; Soriano, V
Expert Opinion on Drug Safety, 12(5): 697-707.
Canadian Journal of Gastroenterology
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines
Coffin, CS; Fung, SK; Ma, MM
Canadian Journal of Gastroenterology, 26(): 917-938.

Journal of Korean Medical Science
Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990-2011
Lee, SH; Kim, KH; Lee, SG; Chen, DH; Jung, DS; Moon, CS; Park, JY; Chung, JS; Kwak, IS; Cho, GJ
Journal of Korean Medical Science, 28(1): 67-73.
European Review for Medical and Pharmacological Sciences
Cryptococcal meningitis in an HIV-1-infected person: relapses or IRIS? Case report and review of the literature
Nunnari, G; Gussio, M; Pinzone, MR; Martellotta, F; Cosentino, S; Cacopardo, B; Celesia, BM
European Review for Medical and Pharmacological Sciences, 17(): 1555-1559.

Antimicrobial Agents and Chemotherapy
Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)
Joly, V; Fagard, C; Grondin, C; Descamps, D; Yazdanpanah, Y; Charpentier, C; de Verdiere, NC; Tabuteau, S; Raffi, F; Cabie, A; Chene, G; Yeni, P
Antimicrobial Agents and Chemotherapy, 57(2): 758-765.
Bmc Nephrology
Long-term risk of mortality for acute kidney injury in HIV-infected patients: a cohort analysis
Lopes, JA; Melo, MJ; Raimundo, M; Fragoso, A; Antunes, F
Bmc Nephrology, 14(): -.
Cadernos De Saude Publica
Trends in non-AIDS-related causes of death among adults with HIV/AIDS, Brazil, 1999 to 2010
Fazito, E; Vasconcelos, AMN; Pereira, MG; de Rezende, DF
Cadernos De Saude Publica, 29(8): 1644-1653.
International Journal of Clinical Practice
Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population
Kakinami, L; Block, RC; Adams, MJ; Cohn, SE; Maliakkal, B; Fisher, SG
International Journal of Clinical Practice, 67(1): 6-13.
Plos One
Changing Risk Behaviours and the HIV Epidemic: A Mathematical Analysis in the Context of Treatment as Prevention
Ramadanovic, B; Vasarhelyi, K; Nadaf, A; Wittenberg, RW; Montaner, JSG; Wood, E; Rutherford, AR
Plos One, 8(5): -.
ARTN e62321
Medicina Clinica
Healthcare resources restrictions and human immunodeficiency virus infection
Soriano, V; Barreiro, P
Medicina Clinica, 141(3): 114-115.
All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART)
Kim, JH; Psevdos, G; Gonzalez, E; Singh, S; Kilayko, MC; Sharp, V
Infection, 41(2): 545-551.
Expert Opinion on Biological Therapy
Using TRIM5 alpha as an HIV therapeutic: the alpha gene?
Anderson, JS
Expert Opinion on Biological Therapy, 13(7): 1029-1038.
American Journal of Transplantation
Human Immunodeficiency Virus in Solid Organ Transplantation
Blumberg, EA; Rogers, CC
American Journal of Transplantation, 13(): 169-178.
Annals Academy of Medicine Singapore
Causes of Death and Factors Associated with Early Death Among Human Immunodeficiency Virus (HIV)-Infected Persons in Singapore: Pre-Highly Active Antiretroviral Therapy (HAART) and Peri-HAART
Chow, A; Tey, J; Win, MK; Leo, YS
Annals Academy of Medicine Singapore, 41(): 563-570.

Annals Academy of Medicine Singapore
Causes of Death in Hospitalised Human Immunodeficiency Virus (HIV)-infected Patients at a National Referral Centre in Singapore: A Retrospective Review from 2008 to 2010
Wong, CS; Lo, FA; Cavailler, P; Ng, OT; Lee, CC; Leo, YS; Chua, AC
Annals Academy of Medicine Singapore, 41(): 571-576.

Annals Academy of Medicine Singapore
Presentation and Outcome Amongst Older Singaporeans Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS): Does Age Alone Drive Excess Mortality?
Huggan, PJ; Foo, RM; Olszyna, D; Chew, NS; Smitasen, N; Mukhopadhyay, A; Archuleta, S
Annals Academy of Medicine Singapore, 41(): 581-586.

Clinical Infectious Diseases
Effect of Statin Therapy in Reducing the Risk of Serious Non-AIDS-Defining Events and Nonaccidental Death
Overton, ET; Kitch, D; Benson, CA; Hunt, PW; Stein, JH; Smurzynski, M; Ribaudo, HJ; Tebas, P
Clinical Infectious Diseases, 56(): 1471-1479.
Cochrane Database of Systematic Reviews
Telephone delivered interventions for reducing morbidity and mortality in people with HIV infection
Gentry, S; van-Velthoven, MHMMT; Car, LT; Car, J
Cochrane Database of Systematic Reviews, (5): -.
ARTN CD009189
Seminars in Nuclear Medicine
FDG-PET Imaging in HIV Infection and Tuberculosis
Sathekge, M; Maes, A; Van de Wiele, C
Seminars in Nuclear Medicine, 43(5): 349-366.
Role of Interleukin-2 in Patients with HIV Infection
Pett, SL; Kelleher, AD; Emery, S
Drugs, 70(9): 1115-1130.

AIDS and Behavior
Smoking Among HIV Positive New Yorkers: Prevalence, Frequency, and Opportunities for Cessation
Tesoriero, JM; Gieryic, SM; Carrascal, A; Lavigne, HE
AIDS and Behavior, 14(4): 824-835.
Temporal evolution of renal involvement in a necropsy study of HIV patients from the pre and HAART eras
Laparra, MCN; Martinez, F; Giner, V; Monteagudo, C; Galindo, MJ; Alcacer, F; Oliver, V; Guix, J; Redon, J
Nefrologia, 30(4): 420-426.
Clinical Infectious Diseases
Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC
Walensky, RP; Paltiel, AD; Losina, E; Morris, BL; Scott, CA; Rhode, ER; Seage, GR; Freedberg, KA
Clinical Infectious Diseases, 51(4): 392-400.
Journal of the American College of Cardiology
HIV and Coronary Heart Disease Time for a Better Understanding
Boccara, F; Lang, S; Meuleman, C; Ederhy, S; Mary-Krause, M; Costagliola, D; Capeau, J; Cohen, A
Journal of the American College of Cardiology, 61(5): 511-523.
International Journal of Environmental Research and Public Health
HIV-Infected Adolescent, Young Adult and Pregnant Smokers: Important Targets for Effective Tobacco Control Programs
Escota, G; Onen, N
International Journal of Environmental Research and Public Health, 10(6): 2471-2499.
Plos One
The Innate Immune Response in HIV/AIDS Septic Shock Patients: A Comparative Study
Amancio, RT; Japiassu, AM; Gomes, RN; Mesquita, EC; Assis, EF; Medeiros, DM; Grinsztejn, B; Bozza, PT; Neto, HCCF; Bozza, FA
Plos One, 8(7): -.
ARTN e68730
International Journal of Clinical Pharmacology and Therapeutics
Evaluation of adverse events associated with antiretroviral therapy and the relationship to treatment adherence
Lenzi, L; Wiens, A; Pontarolo, R
International Journal of Clinical Pharmacology and Therapeutics, 51(2): 141-146.
Clinical Nephrology
Impact of cystatin C elevation and albuminuria on probability of adverse outcomes in HIV-infected men receiving HAART
Yanagisawa, N; Ando, M; Tsuchiya, K; Nitta, K
Clinical Nephrology, 79(5): 362-369.
Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997
van der Helm, J; Geskus, R; Sabin, C; Meyer, L; del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M
Gastroenterology, 144(4): 751-+.
Hepatitis Monthly
Hepatitis B Virus/Human Immunodeficiency Virus Co-Infection and Its Hepatocarcinogenic Potential in Sub-Saharan Black Africans
Kew, MC
Hepatitis Monthly, 12(): -.
ARTN e7876
Journal of Antimicrobial Chemotherapy
Safety and feasibility of treatment simplification to atazanavir/ritonavirlamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitorsatazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)
Di Giambenedetto, S; Fabbiani, M; Colafigli, M; Ciccarelli, N; Farina, S; Sidella, L; D'Avino, A; Mondi, A; Cingolani, A; Tamburrini, E; Murri, R; Navarra, P; Cauda, R; De Luca, A
Journal of Antimicrobial Chemotherapy, 68(6): 1364-1372.
Drug Metabolism and Disposition
In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor
Reese, MJ; Savina, PM; Generaux, GT; Tracey, H; Humphreys, JE; Kanaoka, E; Webster, LO; Harmon, KA; Clarke, JD; Polli, JW
Drug Metabolism and Disposition, 41(2): 353-361.
Bmc Infectious Diseases
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
Prosperi, MCF; Fabbiani, M; Fanti, I; Zaccarelli, M; Colafigli, M; Mondi, A; D'Avino, A; Borghetti, A; Cauda, R; Di Giambenedetto, S
Bmc Infectious Diseases, 12(): -.
ARTN 296
Journal of Infectious Diseases
Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses
Andrade, BB; Hullsiek, KH; Boulware, DR; Rupert, A; French, MA; Ruxrungtham, K; Montes, ML; Price, H; Barreiro, P; Audsley, J; Sher, A; Lewin, SR; Sereti, I
Journal of Infectious Diseases, 207(9): 1379-1388.
AIDS Patient Care and Stds
Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life
Rodriguez-Penney, AT; Iudicello, JE; Riggs, PK; Doyle, K; Ellis, RJ; Letendre, SL; Grant, I; Woods, SP
AIDS Patient Care and Stds, 27(1): 5-16.
European Review for Medical and Pharmacological Sciences
Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic
Pinzone, MR; Di Rosa, M; Malaguarnera, M; Madeddu, G; Foca, E; Ceccarelli, G; D'Ettorre, G; Vullo, V; Fisichella, R; Cacopardo, B; Nunnari, G
European Review for Medical and Pharmacological Sciences, 17(9): 1218-1232.

Virus Research
Reduction of leaf area and symptom severity as proxies of disease-induced plant mortality: The example of the Cauliflower mosaic virus infecting two Brassicaceae hosts
Doumayrou, J; Leblaye, S; Froissart, R; Michalakis, Y
Virus Research, 176(): 91-100.
Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men
Lo, J; Abbara, S; Shturman, L; Soni, A; Wei, J; Rocha-Filho, JA; Nasir, K; Grinspoon, SK
AIDS, 24(2): 243-253.
PDF (398) | CrossRef
Antiretroviral drugs and liver injury
Soriano, V; Puoti, M; Garcia-Gascó, P; Rockstroh, JK; Benhamou, Y; Barreiro, P; McGovern, B
AIDS, 22(1): 1-13.
PDF (257) | CrossRef
Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals
Long, JL; Engels, EA; Moore, RD; Gebo, KA
AIDS, 22(4): 489-496.
PDF (138) | CrossRef
HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years
Abgrall, S; del Giudice, P; Melica, G; Costagliola, D; on behalf of FHDH-ANRS CO4,
AIDS, 24(5): 763-771.
PDF (418) | CrossRef
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, JV; Peng, G; Rapkin, J; Abrams, DI; Silverberg, MJ; MacArthur, RD; Cavert, WP; Henry, WK; Neaton, JD; for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA),
AIDS, 22(7): 841-848.
PDF (193) | CrossRef
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial
Carr, A; Ruxungtham, K; Hirschel, B; Ananworanich, J; on behalf of the STACCATO Study Group, ; Calmy, A; Gayet-Ageron, A; Montecucco, F; Nguyen, A; Mach, F; Burger, F; Ubolyam, S
AIDS, 23(8): 929-939.
PDF (167) | CrossRef
AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study
Buchacz, K; Baker, RK; Palella, FJ; Chmiel, JS; Lichtenstein, KA; Novak, RM; Wood, KC; Brooks, JT; and the HOPS Investigators,
AIDS, 24(10): 1549-1559.
PDF (269) | CrossRef
Metabolic bone disease in HIV infection
Borderi, M; Gibellini, D; Vescini, F; De Crignis, E; Cimatti, L; Biagetti, C; Tampellini, L; Re, MC
AIDS, 23(11): 1297-1310.
PDF (272) | CrossRef
HIV epidemiology and the effects of antiviral therapy on long-term consequences
Quinn, TC
AIDS, 22(): S7-S12.
PDF (129) | CrossRef
Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors
Boccara, F
AIDS, 22(): S19-S26.
PDF (139) | CrossRef
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment
on behalf of the Australian HIV Observational Database, the TREAT Asia HIV Observational Database, ; Falster, K; Choi, JY; Donovan, B; Duncombe, C; Mulhall, B; Sowden, D; Zhou, J; Law, MG
AIDS, 23(17): 2323-2336.
PDF (11481) | CrossRef
The role of HIV in serious diseases other than AIDS
Phillips, AN; Neaton, J; Lundgren, JD
AIDS, 22(18): 2409-2418.
PDF (248) | CrossRef
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
The Antiretroviral Therapy Cohort Collaboration (ART-CC),
AIDS, 22(18): 2481-2492.
PDF (344) | CrossRef
The American Journal of the Medical Sciences
Causes of Death in the Era of Highly Active Antiretroviral Therapy: A Retrospective Analysis of a Hybrid Hematology-Oncology and HIV Practice and the Seattle/King County Adult/Adolescent Spectrum of HIV-Related Diseases Project
The American Journal of the Medical Sciences, 336(3): 217-223.
PDF (160) | CrossRef
Current Opinion in Infectious Diseases
Should HIV therapy be started at a CD4 cell count above 350 cells/μl in asymptomatic HIV-1-infected patients?
Sabin, CA; Phillips, AN
Current Opinion in Infectious Diseases, 22(2): 191-197.
PDF (119) | CrossRef
Therapeutic Drug Monitoring
Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir
Moltó, J; Deig, E; Valle, M; Maria Llibre, J; Miranda, C; Cedeño, S; Valero, S; Negredo, E; Clotet, B
Therapeutic Drug Monitoring, 32(1): 93-96.
PDF (88) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART Era
Brady, MT; Oleske, JM; Williams, PL; Elgie, C; Mofenson, LM; Dankner, WM; Van Dyke, RB; for the Pediatric AIDS Clinical Trials Group219/219C Team,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(1): 86-94.
PDF (295) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Association of HIV Infection, Demographic and Cardiovascular Risk Factors With All-Cause Mortality in the Recent HAART Era
Cockerham, L; Scherzer, R; Zolopa, A; Rimland, D; Lewis, CE; Bacchetti, P; Grunfeld, C; Shlipak, M; Tien, PC
JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(1): 102-106.
PDF (292) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Risk of Hepatitis-Related Mortality Increased Among Hepatitis C Virus/HIV-Coinfected Drug Users Compared With Drug Users Infected Only With Hepatitis C Virus: A 20-Year Prospective Study
Smit, C; van den Berg, C; Geskus, R; Berkhout, B; Coutinho, R; Prins, M
JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(2): 221-225.
PDF (134) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Nonalcoholic Fatty Liver Disease Among HIV-Infected Persons
Crum-Cianflone, N; Dilay, A; Collins, G; Asher, D; Campin, R; Medina, S; Goodman, Z; Parker, R; Lifson, A; Capozza, T; Bavaro, M; Hale, B; Hames, C
JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(5): 464-473.
PDF (122) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Trends in Mortality and Causes of Death Among Women With HIV in the United States: A 10-Year Study
French, AL; Gawel, SH; Hershow, R; Benning, L; Hessol, NA; Levine, AM; Anastos, K; Augenbraun, M; Cohen, MH
JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(4): 399-406.
PDF (340) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Uncontrolled Viral Replication as a Risk Factor for Non-AIDS Severe Clinical Events in HIV-Infected Patients on Long-Term Antiretroviral Therapy: APROCO/COPILOTE (ANRS CO8) Cohort Study
Ferry, T; Raffi, F; Collin-Filleul, F; Dupon, M; Dellamonica, P; Waldner, A; Strady, C; Chêne, G; Leport, C; Moing, VL; and the ANRS CO8 (APROCO-COPILOTE) Study Group,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(4): 407-415.
PDF (258) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure
Uy, J; Armon, C; Buchacz, K; Wood, K; Brooks, JT; the HOPS Investigators,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(4): 450-453.
PDF (162) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Comparison of Clinical Response to Initial Highly Active Antiretroviral Therapy in the Patients in Clinical Care in the United States and Brazil
Grinsztejn, B; Veloso, VG; Pilotto, JH; Campos, DP; Keruly, JC; Moore, RD
JAIDS Journal of Acquired Immune Deficiency Syndromes, 45(5): 515-520.
PDF (130) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)
Lewden, C; May, T; Rosenthal, E; Burty, C; Bonnet, F; Costagliola, D; Jougla, E; Semaille, C; Morlat, P; Salmon, D; Cacoub, P; Chêne, G; on behalf of the ANRS EN19 Mortalité Study Group and Mortavic1,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 48(5): 590-598.
PDF (502) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil
Pacheco, AG; Tuboi, SH; May, SB; Moreira, LF; Ramadas, L; Nunes, EP; Merçon, M; Faulhaber, JC; Harrison, LH; Schechter, M
JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(5): 624-630.
PDF (129) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population
Lewden, C; Chêne, G; Morlat, P; Raffi, F; Dupon, M; Dellamonica, P; Pellegrin, J; Katlama, C; Dabis, F; Leport, C; and the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) CO8 APROCO-COPILOTE and CO3 AQUITAINE Study Groups,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(1): 72-77.
PDF (126) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Survival After AIDS Diagnosis in Italy, 1999-2006: A Population-Based Study
Serraino, D; Zucchetto, A; Suligoi, B; Bruzzone, S; Camoni, L; Boros, S; Paoli, AD; Maso, LD; Franceschi, S; Rezza, G
JAIDS Journal of Acquired Immune Deficiency Syndromes, 52(1): 99-105.
PDF (345) | CrossRef
Sexually Transmitted Diseases
Telephone-Administered Motivational Interviewing to Reduce Risky Sexual Behavior in HIV-Infected Rural Persons: A Pilot Randomized Clinical Trial
Cosio, D; Heckman, TG; Anderson, T; Heckman, BD; Garske, J; McCarthy, J
Sexually Transmitted Diseases, 37(3): 140-146.
PDF (401) | CrossRef
Back to Top | Article Outline

mortality; opportunistic infection; liver; cause of death; trends; HAART

© 2006 Lippincott Williams & Wilkins, Inc.


Article Tools



Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.